NCL Issues a Second Alert to Heed Warnings About Unregulated Versions of GLP-1 Weight Loss Drugs Media Contact: Lisa McDonald, Vice President of Communications, 202-207-2829 Washington, DC A year ago, the National Consumers League took the unusual step of flagging warnings from the Food and Drug Administration (FDA) and medical societies stating that compounded versions of GLP-1 (glucagon-like peptide-1 receptor agonists) weight-loss drugs are not FDA approved and may cause serious health problems
First appearance in Japan
It is believed that Mounjaros tendency to cause electrolyte imbalances, dehydration, blood sugar fluctuations, stress, and fatigue may increase a persons risk
Other possible side effects from GLP-1 medications While not nearly as common, some people may experience other significant side effects with certain GLP-1 medications, such as: Cholecystitis
You can also create a custom pack with YouPack by JumpstartMD , selecting from our full menu of pharmaceutical-grade ingredients